Peg Bio-Pharmaceuticals-B (02565): CR059 selected as a breakthrough in the latest abstract of the ADA 2026 Annual Meeting, innovative strength recognized again.

Hong Kong-listed innovative pharmaceutical company Peg BioMedicine (Hangzhou) Co., Ltd. (stock code: 02565, hereinafter referred to as "Peg BioMed") released a voluntary announcement on April 2nd after the market closed, summarizing the research related to the innovative candidate product CR059 independently developed by the company. The research has been successfully accepted by the American Diabetes Association (ADA) 2026 Scientific Sessions and selected for the Late Breaking Abstract (LBA) section, where it will be presented in poster form during the conference. Following the disclosure of preclinical long-acting data for CR059, the product's recognition at a top global academic conference not only highlights Peg BioMed's leading position in the circRNA technology platform and long-acting GLP-1 field but also indicates that the field of metabolic disease treatment is on the cusp of a new revolution in "monthly/quarterly dosing," providing more convenient treatment options for millions of diabetes and obesity patients worldwide. The authoritative certification at the top conference has led to the inclusion of CR059 in the LBA The American Diabetes Association (ADA) Scientific Sessions is one of the oldest and most influential academic conferences in the field of diabetes and metabolic diseases globally, attracting tens of thousands of top experts, scholars, and pharmaceutical research and development personnel from around the world each year. It serves as a core platform for the dissemination of the latest research findings and clinical practice advancements in the field. The Late Breaking Abstract (LBA) is a category of selected research results focused on at the ADA Sessions, accepting only the most recent, groundbreaking, and clinically relevant research content. The strict selection criteria fully reflect the industry value of the research results and serve as an important recognition of a pharmaceutical company's research and development capabilities and pipeline value. The abstract selected for Peg BioMed's CR059 is titled "CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys." According to the disclosed research results, CR059 demonstrated three core advantages in preclinical studies: firstly, significant weight loss effects and outstanding blood sugar reduction performances, effectively improving the metabolic indicators of the Type 2 diabetes model; secondly, its ultra-long-term expression characteristics establish a core foundation for long-acting treatment; thirdly, based on the company's independently developed circRNA-LNP technology platform, it achieves monthly dosing and is expected to achieve quarterly dosing, supporting sustained expression and long-term metabolic control. The industry significance of this breakthrough is revolutionary: currently marketed mainstream GLP-1 receptor agonists globally, whether Novo Nordisk's semaglutide, Lilly's dulaglutide, or several domestically approved GLP-1 from China, are administered weekly; CR059 extends the dosing cycle from "weekly" to "monthly" and even "quarterly," significantly enhancing patient compliance. Lower dosing frequency means lower rates of missed doses, more stable blood concentration, better treatment outcomes, and higher quality of life, alignment with one of the core pursuits of GLP-1 development globally over the past few decades. circRNA-LNP technology platform: Peg BioMed's "long-acting moat" The long-acting breakthrough of CR059 originates from Peg BioMed's independently developed circRNA-LNP technology platform. Unlike the traditional route of prolonging the half-life of peptides through chemical modifications such as fatty acid side chain conjugation, CR059 adopts a novel circRNA (circular RNA) nucleic acid drug route. CircRNA is a type of closed-loop non-coding RNA that, compared to linear mRNA, does not contain a 5' cap structure and 3' polyA tail and can resist degradation by nucleases in the body, exhibiting extremely high stability and a significantly longer half-life than linear mRNA. Additionally, by integrating the sequence encoding GLP-1 analogue into circRNA and coupling it with mature LNP (lipid nanoparticle) delivery technology, CR059 can continuously express the GLP-1 analogue in the body, achieving the long-acting effect of the drug at the source without depending on chemical modifications to extend the half-life. The advantages of this technology pathway are comprehensive: Ultimate long-acting effect: CircRNA's high stability enables the drug to be continuously expressed in the body, surpassing the half-life ceiling of traditional peptide GLP-1 and potentially allowing for monthly and even quarterly dosing; Enhanced safety: CircRNA does not integrate into the genome in the body, avoiding the risk of insertional mutations. Additionally, LNP delivery technology has been validated with billions of doses globally in mRNA-based COVID-19 vaccines, ensuring sufficient safety; Superb expandability: The circRNA-LNP platform can be used not only for GLP-1 but also for the development of long-acting nucleic acid drugs for other metabolic and chronic diseases, providing Peg BioMed with a rich pipeline reserve and unlocking long-term growth potential. According to the preclinical data disclosed by Peg BioMed previously, CR059 has demonstrated excellent safety and effectiveness in the rhesus monkey model: after a single dose, the expression of the GLP-1 analogue is of ultra-long duration, with significant blood sugar reduction and weight loss effects, and no apparent safety issues. GLP-1 track boom, long-acting and convenience as the next core trend The global GLP-1 market is currently experiencing explosive growth. According to Frost & Sullivan data, the global GLP-1 receptor agonist market size exceeded $80 billion in 2024 and is expected to surpass $150 billion by 2030; in the Chinese market, with the rapid approval and market entry of multiple domestic GLP-1 drugs, the market size is rapidly growing and is expected to reach RMB 120 billion by 2030. Peg BioMed is the only company developing a GLP-1 drug with the potential for quarterly dosing globally. With the circRNA technology pathway, CR059 has achieved a breakthrough in long-acting capability, placing the company at the forefront of GLP-1 research and development globally. Compared to traditional peptide GLP-1, the technological route of CR059 offers intergenerational advantages: the long-acting nature of traditional peptide GLP-1 relies on chemical modifications, with limited potential for half-life extension. In contrast, circRNA nucleic acid drugs achieve long-acting expression from the expression level, theoretically allowing for longer dosing cycles that are difficult to achieve with traditional routes. In addition, with the continuous expansion of indications for metabolic diseases such as obesity, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, the market space for GLP-1 drugs is continuously expanding. CR059 can not only be used for Type 2 diabetes but also expanded to indications such as obesity and NAFLD. Peg BioMedicine, as an innovative pharmaceutical company listed on the Hong Kong stock market, focusing on the research and development of innovative drugs in the field of metabolic diseases, with core technology platforms including circRNA, long-acting peptides, dual-target/multi-target agonists, covering multiple metabolic disease areas such as Type 2 diabetes, obesity, NAFLD. It is one of the core players in the innovative drug race track for metabolic diseases on the Hong Kong stock market. The selection of CR059 for ADA LBA is an important milestone in the company's pipeline progress and a key node in the reshaping of the company's value: 1. Increased academic recognition for global influence: the selection of CR059 for ADA LBA is not only a recognition of CR059 but also an international certification of Peg BioMed's circRNA technology platform, laying a solid foundation for subsequent global clinical development, out-licensing, and global commercialization; 2. Significant increase in pipeline value: as a monthly GLP-1 analogue, CR059 forms a strong competitive position in the global GLP-1 market, and its pipeline value will be reassessed; 3. Highlighted differentiation competitive advantage: Through the circRNA technology pathway, Peg BioMed has differentiated itself in competition with other companies focusing on traditional peptide GLP-1, leading the way in long-acting capability with immense growth potential; 4. Accelerated clinical progress: The recognition at this top conference will accelerate the clinical development process of CR059, with the company likely to swiftly advance to the Investigational New Drug (IND) application, entering the clinical stage and laying the foundation for market approval. For investors, the core investment logic for Peg BioMed lies in cutting-edge technology platforms, a globally leading pipeline, and explosively growing race tracks. Risk warning: Uncertainties still exist in research and commercialization It should be emphasized, as Peg BioMed clearly indicates in the announcement, that CR059 is still in the research stage, and uncertainties remain in the subsequent research and development of candidate products, clinical trial progress, regulatory approvals, and commercialization. Peg BioMed's selection of CR059 for the ADA 2026 LBA is an important milestone in the company's research and development journey and a major breakthrough in the global GLP-1 field. The circRNA technology platform bestows CR059 with the transformative advantage of monthly/quarterly dosing, paving the way for a new era of metabolic disease treatment and providing more convenient treatment options for millions of patients worldwide. With its cutting-edge technology platform and leading pipeline globally, Peg BioMed has the potential to become a dark horse in the field of innovative pharmaceuticals on the Hong Kong stock market. Investors should continue to monitor the clinical development progress of CR059 and the company's pipeline advancement to seize the core investment opportunities in the field of innovative drugs for metabolic diseases.